Rajkot-based manufacturer of pharmaceutical intermediates and APIs (Loxoprofen, Ketoprofen, Dexketoprofen) for pain/inflammation, with CDMO custom manufacturing and nutraceutical products sold across 15 countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 12 | 12 | 12 | 16 | 40 | 53 | 53 |
| Reserves | -10 | -10 | -5 | 5 | 41 | 161 | 177 |
| Borrowings | 54 | 62 | 70 | 81 | 67 | 58 | 44 |
| Other Liabilities | 16 | 21 | 34 | 26 | 34 | 37 | 100 |
| Total Liabilities | 71 | 85 | 112 | 128 | 181 | 309 | 374 |
| AssetsFixed Assets | 29 | 27 | 26 | 27 | 23 | 22 | 58 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 2 | 4 | 1 | 1 | 18 | 1 |
| Other Assets | 43 | 56 | 82 | 100 | 158 | 269 | 315 |
| Total Assets | 71 | 85 | 112 | 128 | 181 | 309 | 374 |
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -15 | -2 | -3 | -3 | -23 | -79 |
| Cash from Investing | -2 | 0 | 0 | -3 | 3 | -36 |
| Cash from Financing | 16 | 3 | 2 | 8 | 19 | 119 |
| SummaryCapital Expenditure | — | — | — | — | — | — |
| Free Cash Flow | -15 | -2 | -3 | -7 | -20 | -116 |
| FCF Margin | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
AHCL · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.